$SLXN 8-K SEC Filings

We, Conyers Trust Company (Cayman) Limited, Registered Office of Silexion Therapeutics Corp (the “Company”) DO HEREBY CERTIFY that the following is a true extract of the ordinary resolution passed at the extraordinary general meeting by ...

Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UN...

Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular

On September 23, 2026, Silexion Therapeutics Corp (the “Company”) reconvened (for the second time) its extraordinary general meeting (the “Meeting”), which had originally been scheduled for September 9, 2026 but had been adjourned due to...

On September 25, 2026, Silexion Therapeutics Corp (the “Company” or “Silexion”) received a letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 c...